Foresight Regulatory Strategy

Vigeo Therapeutics Inc, based in Cambridge, MA, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for various types of cancer to enhance patient outcomes. Their focus lies in reprogramming the tumor immune microenvironment (TIME) through the activation of thrombospondin-1 (Tsp-1), a natural anti-tumorigenic protein that combats cancer cells and inhibits metastasis. Currently, Vigeo is conducting clinical trials for VT1021, a peptide therapeutic agent, in patients with pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with elevated levels of CD36. Their mission is to revolutionize cancer treatment by harnessing the body's own defenses against cancer and improving the lives of those affected by the disease.Generated from the website

The Progeria Research Foundation (PRF) is a dedicated non-profit organization focused on discovering treatments and potential cures for Progeria, an ultra-rare and fatal rapid-aging disease that affects children, leading to heart disease at an average age of 14.5 years. With ongoing research and FDA-approved treatment options like lonafarnib, PRF aims to improve the quality of life and extend the lifespan of those living with this condition. Committed to scientific advancement, PRF conducts numerous clinical trials and partners with international institutions to share knowledge and expertise in Progeria research. With a vision of a world where every child with Progeria is cured, the foundation actively engages with families, volunteers, and supporters to foster awareness, continuity, and innovation in their mission. Generated from the website